Multiple System Atrophy: Recent Developments and Future Perspectives.
MSA
diagnosis
prognosis
treatment
α-synuclein
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
08
07
2019
revised:
03
09
2019
accepted:
15
09
2019
pubmed:
7
11
2019
medline:
9
7
2020
entrez:
7
11
2019
Statut:
ppublish
Résumé
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder characterized by a variable combination of parkinsonism, cerebellar impairment, and autonomic dysfunction. The pathologic hallmark is the accumulation of aggregated α-synuclein in oligodendrocytes, forming glial cytoplasmic inclusions, which qualifies MSA as a synucleinopathy together with Parkinson's disease and dementia with Lewy bodies. The underlying pathogenesis is still not well understood. Some symptomatic treatments are available, whereas neuroprotection remains an urgent unmet treatment need. In this review, we critically appraise significant developments of the past decade with emphasis on pathogenesis, diagnosis, prognosis, and treatment development. We further discuss unsolved questions and highlight some perspectives. © 2019 International Parkinson and Movement Disorder Society.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1629-1642Informations de copyright
© 2019 International Parkinson and Movement Disorder Society.
Références
Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71(9):670-676.
Lopez-Cuina M, Foubert-Samier A, Tison F, Meissner WG. Present and future of disease-modifying therapies in multiple system atrophy. Auton Neurosci 2018;211:31-38.
Krismer F, Wenning GK. Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat Rev Neurol 2017;13(4):232-243.
Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989;94(1-3):79-100.
Quinn N. Multiple system atrophy-the nature of the beast. J Neurol Neurosurg Psychiatry 1989(Suppl):78-89.
Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998;251(3):205-208.
Miller DW, Johnson JM, Solano SM, Hollingsworth ZR, Standaert DG, Young AB. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm (Vienna) 2005;112(12):1613-1624.
Jin H, Ishikawa K, Tsunemi T, Ishiguro T, Amino T, Mizusawa H. Analyses of copy number and mRNA expression level of the alpha-synuclein gene in multiple system atrophy. J Med Dent Sci 2008;55(1):145-153.
Fernagut PO, Tison F. Animal models of multiple system atrophy. Neuroscience 2012;211:77-82.
Kahle PJ, Neumann M, Ozmen L, et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002;3(6):583-588.
Shults CW, Rockenstein E, Crews L, et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 2005;25(46):10689-10699.
Yazawa I, Giasson BI, Sasaki R, et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005;45(6):847-859.
Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163(1):94-98.
Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000;54(3):697-702.
Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004;19(12):1391-1402.
Schrag A, Selai C, Mathias C, et al. Measuring health-related quality of life in MSA: the MSA-QoL. Mov Disord 2007;22(16):2332-2338.
Holmberg B, Johansson JO, Poewe W, et al. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 2007;22(8):1138-1144.
Laurens B, Vergnet S, Lopez MC, et al. Multiple System Atrophy - State of the Art. Curr Neurol Neurosci Rep 2017;17(5):41.
Asi YT, Simpson JE, Heath PR, et al. Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia 2014;62(6):964--970.
Djelloul M, Holmqvist S, Boza-Serrano A, et al. Alpha-Synuclein Expression in the Oligodendrocyte Lineage: an in vitro and in vivo Study Using Rodent and Human Models. Stem Cell Reports 2015;5(2):174-184.
Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009;106(31):13010-13015.
Rockenstein E, Ubhi K, Inglis C, et al. Neuronal to oligodendroglial alpha-synuclein redistribution in a double transgenic model of multiple system atrophy. Neuroreport 2012;23(4):259-264.
Kisos H, Pukass K, Ben-Hur T, Richter-Landsberg C, Sharon R. Increased neuronal alpha-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling alpha-synucleinopathies. PLoS One 2012;7(10):e46817.
Luk KC, Kehm V, Carroll J, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012;338(6109):949-953.
Cavaliere F, Cerf L, Dehay B, et al. In vitro alpha-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains. Neurobiol Dis 2017;103:101-112.
Rostami J, Holmqvist S, Lindstrom V, et al. Human Astrocytes Transfer Aggregated Alpha-Synuclein via Tunneling Nanotubes. J Neurosci 2017;37(49):11835-11853.
Hansen C, Angot E, Bergstrom AL, et al. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011;121(2):715-725.
Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 2014;62(3):387-398.
Kaji S, Maki T, Kinoshita H, et al. Pathological Endogenous alpha-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy. Stem Cell Reports 2018;10(2):356-365.
Yu Z, Shi M, Stewart T, et al. Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. In revision.
Cykowski MD, Coon EA, Powell SZ, et al. Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain 2015;138(Pt 8):2293-2309.
Sekiya H, Kowa H, Koga H, et al. Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation. Acta Neuropathol 2019;137(3):455-466.
Lopez-Cuina M, Fernagut PO, Canron MH, et al. Deep brain stimulation does not enhance neuroinflammation in multiple system atrophy. Neurobiol Dis 2018;118:155-160.
Nykjaer CH, Brudek T, Salvesen L, Pakkenberg B. Changes in the cell population in brain white matter in multiple system atrophy. Mov Disord 2017;32(7):1074-1082.
Salvesen L, Ullerup BH, Sunay FB, et al. Changes in total cell numbers of the basal ganglia in patients with multiple system atrophy - A stereological study. Neurobiol Dis 2015;74:104-113.
Ahmed Z, Asi YT, Lees AJ, Revesz T, Holton JL. Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and Parkinson's disease. Brain Pathol 2013;23(3):263-273.
May VE, Ettle B, Poehler AM, et al. alpha-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy. Neurobiol Aging 2014;35(10):2357-2368.
Song YJ, Lundvig DM, Huang Y, et al. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 2007;171(4):1291-1303.
Ota K, Obayashi M, Ozaki K, et al. Relocation of p25alpha/tubulin polymerization promoting protein from the nucleus to the perinuclear cytoplasm in the oligodendroglia of sporadic and COQ2 mutant multiple system atrophy. Acta Neuropathol Commun 2014;2:136.
Mavroeidi P, Arvanitaki F, Karakitsou AK, et al. Endogenous oligodendroglial alpha-synuclein and TPPP/p25alpha orchestrate alpha-synuclein pathology in experimental multiple system atrophy models. Acta Neuropathol 2019;138(3):415-441.
Prusiner SB, Woerman AL, Mordes DA, et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A 2015;112(38):E5308-5317.
Watts JC, Giles K, Oehler A, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A 2013;110(48):19555-19560.
Woerman AL, Kazmi SA, Patel S, et al. MSA prions exhibit remarkable stability and resistance to inactivation. Acta Neuropathol 2018;135(1):49-63.
Peelaerts W, Bousset L, Van der Perren A, et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015;522(7556):340-344.
Peng C, Gathagan RJ, Covell DJ, et al. Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies. Nature 2018;557(7706):558-563.
Dhillon JS, Trejo-Lopez JA, Riffe C, et al. Comparative analyses of the in vivo induction and transmission of alpha-synuclein pathology in transgenic mice by MSA brain lysate and recombinant alpha-synuclein fibrils. Acta Neuropathol Commun 2019;7(1):80.
Wenning G, Trojanowski JQ, Kaufmann H, Wisniewski T, Rocca WA, Low PA. Is multiple system atrophy an infectious disease? Ann Neurol 2018;83(1):10-12.
Duda JE, Giasson BI, Gur TL, et al. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol 2000;59(9):830-841.
Campbell BC, McLean CA, Culvenor JG, et al. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem 2001;76(1):87-96.
Tanji K, Miki Y, Mori F, et al. A mouse model of adult-onset multiple system atrophy. Neurobiol Dis 2019;127:339-349.
Bassil F, Guerin PA, Dutheil N, et al. Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy. Mov Disord 2017;32(8):1230-1239.
Mandel RJ, Marmion DJ, Kirik D, et al. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun 2017;5(1):47.
Flabeau O, Meissner WG, Ozier A, Berger P, Tison F, Fernagut PO. Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy. Mov Disord 2014;29(3):388-395.
Boudes M, Uvin P, Pinto S, et al. Bladder dysfunction in a transgenic mouse model of multiple system atrophy. Mov Disord 2013;28(3):347-355.
Kuzdas D, Stemberger S, Gaburro S, Stefanova N, Singewald N, Wenning GK. Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: experimental evidence. Exp Neurol 2013;247:531-536.
Federoff M, Price TR, Sailer A, et al. Genome-wide estimate of the heritability of Multiple System Atrophy. Parkinsonism Relat Disord 2016;22:35-41.
Sailer A, Scholz SW, Nalls MA, et al. A genome-wide association study in multiple system atrophy. Neurology 2016;87(15):1591-1598.
Multiple-System Atrophy Research C. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 2013;369(3):233-244.
Jeon BS, Farrer MJ, Bortnick SF, Korean Canadian Alliance on Parkinson's D, Related D. Mutant COQ2 in multiple-system atrophy. N Engl J Med 2014;371(1):80.
Lin CH, Tan EK, Yang CC, Yi Z, Wu RM. COQ2 gene variants associate with cerebellar subtype of multiple system atrophy in Chinese. Mov Disord 2015;30(3):436-437.
Ogaki K, Fujioka S, Heckman MG, et al. Analysis of COQ2 gene in multiple system atrophy. Mol Neurodegener 2014;9:44.
Ronchi D, Di Biase E, Franco G, et al. Mutational analysis of COQ2 in patients with MSA in Italy. Neurobiol Aging 2016;45:213 e211-213 e212.
Schottlaender LV, Houlden H, Multiple-System Atrophy Brain Bank C. Mutant COQ2 in multiple-system atrophy. N Engl J Med 2014;371(1):81.
Sharma M, Wenning G, Kruger R, European Multiple-System Atrophy Study G. Mutant COQ2 in multiple-system atrophy. N Engl J Med 2014;371(1):80-81.
Sun Z, Ohta Y, Yamashita T, et al. New susceptible variant of COQ2 gene in Japanese patients with sporadic multiple system atrophy. Neurol Genet 2016;2(2):e54.
Procopio R, Gagliardi M, Brighina L, et al. Genetic mutation analysis of the COQ2 gene in Italian patients with multiple system atrophy. Gene 2019:20:144037.
Mokretar K, Pease D, Taanman JW, et al. Somatic copy number gains of alpha-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains. Brain 2018;141(8):2419-2431.
Heckman MG, Schottlaender L, Soto-Ortolaza AI, et al. LRRK2 exonic variants and risk of multiple system atrophy. Neurology 2014;83(24):2256-2261.
Ozelius LJ, Foroud T, May S, et al. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord 2007;22(4):546-549.
Riboldi GM, Palma JA, Cortes E, et al. Early-onset pathologically proven multiple system atrophy with LRRK2 G2019S mutation. Mov Disord 2019;34(7):1080-1082.
Mitsui J, Matsukawa T, Sasaki H, et al. Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol 2015;2(4):417-426.
Sklerov M, Kang UJ, Liong C, et al. Frequency of GBA variants in autopsy-proven multiple system atrophy. Mov Disord Clin Pract 2017;4(4):574-581.
Pasanen P, Myllykangas L, Siitonen M, et al. Novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol Aging 2014;35(9):2180 e2181-2185.
Kiely AP, Asi YT, Kara E, et al. alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol 2013;125(5):753-769.
Stamelou M, Quinn NP, Bhatia KP. “Atypical” atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide. Mov Disord 2013;28(9):1184-1199.
Stankovic I, Quinn N, Vignatelli L, et al. A critique of the second consensus criteria for multiple system atrophy. Mov Disord 2019;34(7):976-984.
Cortese A, Simone R, Sullivan R, et al. Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. Nat Genet 2019;51(4):649-658.
Kollensperger M, Geser F, Ndayisaba JP, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010;25(15):2604-2612.
Osaki Y, Ben-Shlomo Y, Lees AJ, Wenning GK, Quinn NP. A validation exercise on the new consensus criteria for multiple system atrophy. Mov Disord 2009;24(15):2272-2276.
Koga S, Aoki N, Uitti RJ, et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 2015;85(5):404-412.
Miki Y, Foti SC, Asi YT, et al. Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain 2019;142(9):2813-2827.
Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002;125(Pt 5):1070-1083.
Kim HJ, Jeon BS, Lee JY, Yun JY. Survival of Korean patients with multiple system atrophy. Mov Disord 2011;26(5):909-912.
Coon EA, Sletten DM, Suarez MD, et al. Clinical features and autonomic testing predict survival in multiple system atrophy. Brain 2015;138(Pt 12):3623-3631.
Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. Natural history of pure autonomic failure: A United States prospective cohort. Ann Neurol 2017;81(2):287-297.
Singer W, Berini SE, Sandroni P, et al. Pure autonomic failure: Predictors of conversion to clinical CNS involvement. Neurology 2017;88(12):1129-1136.
Coon EA, Fealey RD, Sletten DM, et al. Anhidrosis in multiple system atrophy involves pre- and postganglionic sudomotor dysfunction. Mov Disord 2017;32(3):397-404.
Orimo S, Kanazawa T, Nakamura A, et al. Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 2007;113(1):81-86.
Nagayama H, Ueda M, Yamazaki M, Nishiyama Y, Hamamoto M, Katayama Y. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord 2010;25(11):1744-1747.
Provitera V, Nolano M, Caporaso G, et al. Postganglionic sudomotor denervation in patients with multiple system atrophy. Neurology 2014;82(24):2223-2229.
Goldstein DS, Cheshire WP Jr. Roles of cardiac sympathetic neuroimaging in autonomic medicine. Clin Auton Res 2018;28(4):397-410.
Doppler K, Weis J, Karl K, et al. Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy. Mov Disord 2015;30(12):1688-1692.
Zange L, Noack C, Hahn K, Stenzel W, Lipp A. Phosphorylated alpha-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Brain 2015;138(Pt 8):2310-2321.
Stankovic I, Krismer F, Jesic A, et al. Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord 2014;29(7):857-867.
Ory-Magne F, Pellaprat J, Harroch E, et al. Abnormal pain perception in patients with Multiple System Atrophy. Parkinsonism Relat Disord 2018;48:28-33.
Benrud-Larson LM, Sandroni P, Schrag A, Low PA. Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord 2005;20(8):951-957.
Goldstein DS, Holmes C, Bentho O, et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008;14(8):600-607.
Krismer F, Pinter B, Mueller C, et al. Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism. Parkinsonism Relat Disord 2017;35:36-41.
Suzuki M, Hashimoto M, Yoshioka M, Murakami M, Kawasaki K, Urashima M. The odor stick identification test for Japanese differentiates Parkinson's disease from multiple system atrophy and progressive supra nuclear palsy. BMC Neurol 2011;11:157.
Huppertz HJ, Moller L, Sudmeyer M, et al. Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. Mov Disord 2016;31(10):1506-1517.
Scherfler C, Gobel G, Muller C, et al. Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. Neurology 2016;86(13):1242-1249.
Barbagallo G, Sierra-Pena M, Nemmi F, et al. Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Mov Disord 2016;31(3):325-334.
Peran P, Barbagallo G, Nemmi F, et al. MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy. Mov Disord 2018;33(4):600-608.
Krismer F, Seppi K, Gobel G, et al. Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. Mov Disord 2019;34(7):1041-1048.
Nemmi F, Pavy-Le Traon A, Phillips OR, et al. A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control. Neuroimage Clin 2019;23:101858.
Vergnet S, Hives F, Foubert-Samier A, et al. Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. Parkinsonism Relat Disord 2019;63:190-203.
Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 2004;127(Pt 12):2657-2671.
Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010;9(2):149-158.
Eckert T, Tang C, Ma Y, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord 2008;23(5):727-733.
Poston KL, Tang CC, Eckert T, et al. Network correlates of disease severity in multiple system atrophy. Neurology 2012;78(16):1237-1244.
Tripathi M, Tang CC, Feigin A, et al. Automated Differential Diagnosis of Early Parkinsonism Using Metabolic Brain Networks: A Validation Study. J Nucl Med 2016;57(1):60-66.
Holtbernd F, Gagnon JF, Postuma RB, et al. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology 2014;82(7):620-627.
Laurens B, Constantinescu R, Freeman R, et al. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. Neurobiol Dis 2015;80:29-41.
Low PA, Reich SG, Jankovic J, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 2015;14(7):710-719.
Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013;12(3):264-274.
Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997;48(2):384-393.
O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008;131(Pt 5):1362-1372.
Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y. Survival in multiple system atrophy. Mov Disord 2008;23(2):294-296.
Starhof C, Korbo L, Lassen CF, Winge K, Friis S. Clinical Features in a Danish Population-Based Cohort of Probable Multiple System Atrophy Patients. Neuroepidemiology 2016;46(4):261-267.
Petrovic IN, Ling H, Asi Y, et al. Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord 2012;27(9):1186-1190.
Meissner WG, Laurencin C, Tranchant C, et al. Outcome of deep brain stimulation in slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature. Parkinsonism Relat Disord 2016;24:69-75.
Giannini G, Calandra-Buonaura G, Mastrolilli F, et al. Early stridor onset and stridor treatment predict survival in 136 patients with MSA. Neurology 2016;87(13):1375-1383.
Fanciulli A, Jordan J, Biaggioni I, et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS) : Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res 2018;28(4):355-362.
Poewe W, Seppi K, Fitzer-Attas CJ, et al. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol 2015;14(2):145-152.
Lee PH, Lee JE, Kim HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012;72(1):32-40.
Meissner WG, Pavy-Le Traon A, Foubert-Samier A, et al. Specific active immunotherapy (SAIT) against alpha-synuclein with AFFITOPE® PD01A and PD03A: results from the AFF009 phase I trial. Mov Disord 2018;33(Suppl 2). https://www.mdsabstracts.org/abstract/specific-active-immunotherapy-sait-against-alpha-synuclein-with-affitope-pd01a-and-pd03a-results-from-the-aff009-phase-i-trial/.
Seppi K, Schocke MF, Mair KJ, et al. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. Neuroimage 2006;31(1):240-245.
Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain 2006;129(Pt 4):1040-1049.
Pellecchia MT, Barone P, Vicidomini C, et al. Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study. Mov Disord 2011;26(7):1303-1309.
Horimoto Y, Aiba I, Yasuda T, et al. Cerebral atrophy in multiple system atrophy by MRI. J Neurol Sci 2000;173(2):109-112.
Konagaya M, Konagaya Y, Sakai M, Matsuoka Y, Hashizume Y. Progressive cerebral atrophy in multiple system atrophy. J Neurol Sci 2002;195(2):123-127.
Hauser TK, Luft A, Skalej M, et al. Visualization and quantification of disease progression in multiple system atrophy. Mov Disord 2006;21(10):1674-1681.
Lee JH, Kim TH, Mun CW, Kim TH, Han YH. Progression of subcortical atrophy and iron deposition in multiple system atrophy: a comparison between clinical subtypes. J Neurol 2015;262(8):1876-1882.
Reginold W, Lang AE, Marras C, Heyn C, Alharbi M, Mikulis DJ. Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 2014;20(2):222-225.
Levin J, Maass S, Schuberth M, et al. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2019;18(8):724-735.
Johnson EB, Byrne LM, Gregory S, et al. Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology 2018;90(8):e717-e723.
Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84(22):2247-2257.
Rojas JC, Bang J, Lobach IV, et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 2018;90(4):e273-e281.
Rojas JC, Karydas A, Bang J, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 2016;3(3):216-225.
Perez-Lloret S, Flabeau O, Fernagut PO, et al. Current Concepts in the Treatment of Multiple System Atrophy. Mov Disord Clin Pract 2015;2(1):6-16.
Bassil F, Fernagut PO, Bezard E, et al. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci U S A 2016;113(34):9593-9598.
Heras-Garvin A, Weckbecker D, Ryazanov S, et al. Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord 2019;34(2):255-263.
Mandler M, Valera E, Rockenstein E, et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 2015;10:10.
Valera E, Spencer B, Fields JA, et al. Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathol Commun 2017;5(1):2.
Herrera-Vaquero M, Bouquio D, Kallab M, et al. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent alpha-synuclein in experimental multiple system atrophy. Biochim Biophys Acta Mol Basis Dis 2019;1865(11):166513.
Spencer B, Valera E, Rockenstein E, Trejo-Morales M, Adame A, Masliah E. A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy. Mol Neurodegener 2015;10:48.
Arotcarena ML, Bourdenx M, Dutheil N, et al. Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies. JCI Insight 2019;4(16).
Ettle B, Kerman BE, Valera E, et al. alpha-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy. Acta Neuropathol 2016;132(1):59-75.
Bassil F, Canron MH, Vital A, et al. Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain 2017;140(5):1420-1436.
Venezia S, Refolo V, Polissidis A, Stefanis L, Wenning GK, Stefanova N. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal alpha-synucleinopathy. Mol Neurodegener 2017;12(1):52.
Sturm E, Fellner L, Krismer F, Poewe W, Wenning GK, Stefanova N. Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. Neurotherapeutics 2016;13(4):871-879.
Stefanova N. Translational therapies for multiple system atrophy: Bottlenecks and future directions. Auton Neurosci 2018;211:7-14.
Dodel R, Spottke A, Gerhard A, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010;25(1):97-107.
Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009;132(Pt 1):156-171.
Low PA, Robertson D, Gilman S, et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13(3):268-275.
Mullen JA, Savage AB, Minkwitz C, et al. Safety, biomarker effects, and efficacy of the myeloperoxidase inhibitor AZD3241in patients with multiple system atrophy: a 12-week randomized multicenter PET study. Clin Auton Res 2018;28:144.
Rascol O, French MSA-Fluoxetine Study Group. Preliminary results of the French MSA fluoxetine study. Eur J Neurol 2012;19(Suppl 1):262.
Singer W, Dietz AB, Zeller AD, et al. Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. Neurology 2019;93(1):e77-e87.
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129-2170.
Walsh RR, Krismer F, Galpern WR, et al. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology 2018;90(2):74-82.
Fernagut PO, Dehay B, Maillard A, et al. Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiol Dis 2014;67:133-139.
Dehay B, Bourdenx M, Gorry P, et al. Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol 2015;14(8):855-866.